WO2026013449 - OXAZOLIDONE-DERIVED COMPOUNDS AND THEIR USE IN THE TREATMENT OF CHRONIC AND ACUTE PAIN
National phase entry is expected:
Publication Number
WO/2026/013449
Publication Date
15.01.2026
International Application No.
PCT/IB2025/000357
International Filing Date
11.07.2025
Title **
[English]
OXAZOLIDONE-DERIVED COMPOUNDS AND THEIR USE IN THE TREATMENT OF CHRONIC AND ACUTE PAIN
[French]
COMPOSÉS DÉRIVÉS D'OXAZOLIDONE ET LEUR UTILISATION DANS LE TRAITEMENT DE LA DOULEUR CHRONIQUE ET AIGUË
Applicants **
SEA4US - BIOTECNOLOGIA E RECURSOS MARINHOS, SA
Inventors
DOS SANTOS BALTAZAR DE LIMA, Pedro, Afonso
PINHEIRO COSTA BASTOS, André, Emanuel
FERREIRA DA SILVA MOURA, José, Eduardo
SZWARC DOS SANTOS, Beatriz
MAÇO ABREU, Ana, Rosa
CHEGÃO PISSARRA MONTEIRO, Ana, Alexandra
SEGÃO MONDRAGÃO, Miguel, Ângelo
PEREIRA, Ana Isabel, Pimenta, Gonçalves
ALHINHO BERNARDO, Ana, Fátima
TREMBLEAU, Laurent, Alain, Claude
VAN BERKOM., Leonardus, Wilhelmus, Adriaan
MATEUS AFONSO, Carlos, Alberto
MOREIRA, Rui, Ferreira, Alves
Priority Data
63/669,908
11.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3334 | |
| EPO | Filing, Examination, Granting | 14411 | |
| Japan | Filing, Examination, Granting | 2265 | |
| South Korea | Filing, Examination, Granting | 2222 | |
| USA | Filing, Examination, Granting | 6240 |
Total:
28,472
Contact Us
Abstract[English]
currents expressed in the small diameter dorsal root neurons (sdDRGns). Such findings, together with those showing that oxazolidone and oxazolidone analogue compounds act as activity dependent blockers also lead to very reduced side-effects. The results disclosed herein show that oxazolidone and oxazolidone analogue compounds described herein are a viable alternative to the already existing pharmaceutical compounds used in the treatment of pain.[French]
à tension activée exprimés dans les neurones à racines dorsales de petit diamètre (sdDRGn). De telles découvertes, conjointement avec celles révèlant que l'oxazolidone et les composés analogues d'oxazolidone agissent en tant que bloqueurs dépendant de l'activité, produisent également des effets secondaires très réduits. Les résultats divulgués révèlent que l'oxazolidone et les composés analogues d'oxazolidone présentés dans la divulgation sont une alternative viable aux composés pharmaceutiques déjà existants utilisés dans le traitement de la douleur.